Aspire BioPharma is trading 5.24% down at $7.55 after no clear company-specific catalyst was identified for August 24, 2026.

  • Completed the Dura Driver Control Systems acquisition on August 10.
  • Held an investor conference on August 19–20; available coverage does not directly connect either event to the pre-market decline.
  • The Nasdaq Composite is down 0.55%, reflecting modestly risk-off sentiment, but that alone does not clearly explain the move.